Mazdutide vs Sermorelin
Extensively Studied vs Well Studied
monitor Mechanism-based · 47% Both Mazdutide and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Mazdutide Sermorelin
Weight 4,563.1 Da 3,358 Da
Half-life 6-8 days 10-12 minutes
Chain 33 amino acids 29 amino acids
Type Oxyntomodulin analog with fatty acid conjugation GHRH analog
Key Benefits
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Mazdutide Sermorelin
Status Extensively Studied Well Studied
References 4 studies 5 studies
Latest — November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.